Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate76K: Adjuvant Nivolumab vs Placebo in Resected Stage IIB/C Melanoma
NCT04099251Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of nivolumab in melanoma, sponsored by Bristol Myers Squibb. Started Oct 2019; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04099251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099251.